GoodRx Holdings, Inc. GDRX
3.53 USD -0.13 (-3.42%)
Nov 12, 2026, 3:28 PM EST
3.47 Day range 3.64
1.77 52-week range 3.89
- YTD
- +30.07%
- 1 year
- +15.20%
News
businesswire.com GoodRx Brings Prescription Pricing Intelligence to Google Cloud's Gemini for Healthcare SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the trusted platform for prescription access and affordability in the U.S., today announced it is a launch partner for Google Cloud's…
benzinga.com GoodRx Rolls Out Its Employer Direct Weight Loss Offering For GLP-1 Medications GoodRx (Nasdaq: GDRX), the trusted platform for prescription access and affordability in the U.S., today announced the market-wide launch of its Employer Direct weight loss offering, giving employers…
benzinga.com Full Transcript: GoodRx Holdings Q2 2026 Earnings Call GoodRx Holdings (NASDAQ:GDRX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call…
benzinga.com Barclays Maintains Underweight on GoodRx Holdings, Raises Price Target to $4 Barclays analyst Glen Santangelo maintains GoodRx Holdings (NASDAQ:GDRX) with a Underweight and raises the price target from $3 to $4.
benzinga.com UBS Maintains Neutral on GoodRx Holdings, Raises Price Target to $3.75 UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and raises the price target from $2.5 to $3.75.
benzinga.com Citigroup Maintains Buy on GoodRx Holdings, Raises Price Target to $5 Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $4 to $5.
benzinga.com TD Cowen Maintains Buy on GoodRx Holdings, Raises Price Target to $5 TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $4 to $5.- benzinga.com GoodRx Holdings Raises FY2026 Sales Guidance from $765.000M-$785.000M to $790.000M-$805.000M vs $775.751M Est GoodRx Holdings (NASDAQ:GDRX) raises FY2026 sales outlook from $765.000 million-$785.000 million to $790.000 million-$805.000 million vs $775.751 million estimate.
- benzinga.com GoodRx Holdings Q2 Adj. EPS $0.08, Inline, Sales $200.411M Beat $193.162M Estimate GoodRx Holdings (NASDAQ:GDRX) reported quarterly earnings of $0.08 per share which met the analyst consensus estimate. This is a 11.11 percent decrease over earnings of $0.09 per share from the same…
benzinga.com GoodRx Launches Its $14.99 Per Month Subscription Service, GoodRx Companion New service brings together free and low-cost generic medications, affordable online care visits, and savings on additional healthcare services in one simple program. Built for a healthcare…- benzinga.com Citigroup Maintains Buy on GoodRx Holdings, Raises Price Target to $4 Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $3.5 to $4.
benzinga.com Why Jim Cramer Says 'Pull The Trigger' On Chevron Cramer recommends buying Chevron (CVX) due to good cash flow and limited downside, and waiting to buy Vertiv (VRT) on a decline. GoodRx (GDRX) reports mixed earnings, Sterling Infrastructure (STRL)…- benzinga.com TD Cowen Maintains Buy on GoodRx Holdings, Raises Price Target to $4 TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $3 to $4.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com GoodRx Holdings Raises FY2026 Sales Guidance from $750.000M-$780.000M to $765.000M-$785.000M vs $764.443M Est GoodRx Holdings (NASDAQ:GDRX) raises FY2026 sales outlook from $750.000 million-$780.000 million to $765.000 million-$785.000 million vs $764.443 million estimate.- benzinga.com GoodRx Holdings Q1 Adj. EPS $0.07, Inline, Sales $194.006M Beat $185.137M Estimate GoodRx Holdings (NASDAQ:GDRX) reported quarterly earnings of $0.07 per share which met the analyst consensus estimate. This is a 22.22 percent decrease over earnings of $0.09 per share from the same…
- benzinga.com GoodRx Providing Access To Novo Nordisk's Ozempic Pill At $149/Month GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced that it is providing access to self-pay pricing for Novo Nordisk's Ozempic® pill (oral semaglutide),…
benzinga.com GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market GoodRx shares rise as Wegovy HD rollout expands self-pay access, with tiered pricing and mixed technical signals.- benzinga.com GoodRx Says New Higher Dose Wegovy HD Injection 7.2 Mg Is Now Available To Eligible Self-Pay Patients On GoodRx At $399 Per Month Expands access to FDA-approved GLP-1 treatment with transparent pricing and integrated support through GoodRx for Weight LossBrief Summary:Wegovy® HD is now available on GoodRx at a self-pay price of…
benzinga.com What's Going On With GoodRx Stock Thursday? GoodRx shares rise after expanding Eli Lilly's GLP-1 access; analysts keep Buy rating ahead of May earnings.- benzinga.com GoodRx Working With Eli Lilly To Expand Access To FDA-Approved Foundayo At $149/Month GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is working with Eli Lilly and Company to expand access to the newly FDA-approved oral GLP-1…
benzinga.com GoodRx Partners With Viatris To Offer Major Brand Medications At A Discount Collaboration expands access to trusted therapies with discounted cash prices for leading brands including Lipitor®, Celebrex®, Viagra®, and Norvasc®GoodRx (NASDAQ:GDRX), the leading platform for- benzinga.com Wells Fargo Maintains Overweight on GoodRx Holdings, Lowers Price Target to $3.5 Wells Fargo analyst Stan Berenshteyn maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight and lowers the price target from $7 to $3.5.
- benzinga.com Citigroup Maintains Buy on GoodRx Holdings, Lowers Price Target to $3.5 Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and lowers the price target from $4.5 to $3.5.
- benzinga.com Goldman Sachs Maintains Neutral on GoodRx Holdings, Lowers Price Target to $2.5 Goldman Sachs analyst Eric Sheridan maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and lowers the price target from $4 to $2.5.
- benzinga.com Mizuho Maintains Neutral on GoodRx Holdings, Lowers Price Target to $3 Mizuho analyst Steven Valiquette maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and lowers the price target from $4 to $3.
benzinga.com A Glimpse Into The Expert Outlook On GoodRx Holdings Through 4 Analysts 
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com C3.ai Posts Downbeat Results, Joins Trade Desk, FTAI Aviation And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why Marriott Vacations Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - benzinga.com Earnings Scheduled For February 25, 2026
- benzinga.com Amazon Beats Google's Capex; Negative Sentiment Is Good; Tradable Low Points For Stocks, Gold, Silver, And Bitcoin Sentiment Change Creates Opportunity
- benzinga.com 60 Degrees Pharmaceuticals Partners With GoodRx To Expand Access To ARAKODA GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine)Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company's marketing strategyPartnership…
- benzinga.com Demystifying GoodRx Holdings: Insights From 8 Analyst Reviews
- benzinga.com Jefferies Downgrades GoodRx Holdings to Hold, Lowers Price Target to $2.75 Jefferies analyst Glen Santangelo downgrades GoodRx Holdings (NASDAQ:GDRX) from Buy to Hold and lowers the price target from $5.25 to $2.75.
- benzinga.com Citigroup Maintains Buy on GoodRx Holdings, Lowers Price Target to $4.5 Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and lowers the price target from $5 to $4.5.
benzinga.com Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost Novo Nordisk launches Wegovy weight loss pill in the US, showing up to 17% weight loss, with prices starting near $5 a day and broad pharmacy and telehealth access.- benzinga.com Morgan Stanley Maintains Equal-Weight on GoodRx Holdings, Lowers Price Target to $4 Morgan Stanley analyst Craig Hettenbach maintains GoodRx Holdings (NASDAQ:GDRX) with a Equal-Weight and lowers the price target from $5 to $4.
- benzinga.com 60 Degrees Pharma To Expand ARAKODA Sales And Marketing, Adding Reps, GoodRx Partnership And Enhanced Digital Campaign 6-month commercial pilot demonstrated increasing demand among prescribersExpansion plan includes doubling the number of sales reps, a new GoodRx partnership, and enhanced digital marketing…
benzinga.com Barclays Initiates Coverage On GoodRx Holdings with Underweight Rating, Announces Price Target of $3 Barclays analyst Glen Santangelo initiates coverage on GoodRx Holdings (NASDAQ:GDRX) with a Underweight rating and announces Price Target of $3.
benzinga.com Novo Nordisk Leans Into Affordability Amid Rising Competition Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger Wegovy pill rollout.- benzinga.com JP Morgan Maintains Overweight on GoodRx Holdings, Lowers Price Target to $5 JP Morgan analyst Lisa Gill maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight and lowers the price target from $6 to $5.
- benzinga.com TD Cowen Maintains Buy on GoodRx Holdings, Lowers Price Target to $6 TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and lowers the price target from $7 to $6.
- benzinga.com CBS Reporter Jennifer Jacobs Posts On X "News: Other drug websites such as GoodRx won't be partnering with TrumpRx, sources told me. One official cleared up misunderstandings about what TrumpRx will be, saying the federal govt website will send consumers to the pharmaceutical companies' websites, where they can purchase buy prescription drugs directly. The companies will decide how to fulfill those orders – via their own in-house logistics or by partnering with a 3rd-party platform" https://x.com/JenniferJJacobs/status/1986518429478568383
- benzinga.com UBS Maintains Neutral on GoodRx Holdings, Lowers Price Target to $4 UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and lowers the price target from $4.25 to $4.
- benzinga.com GoodRx Holdings Q3 Adj. EPS $0.08 Misses $0.09 Estimate, Sales $196.028M Beat $194.550M Estimate GoodRx Holdings (NASDAQ:GDRX) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.09 by 12.09 percent. This is unchanged from the same period last year.…
benzinga.com Earnings Scheduled For November 4, 2025 
benzinga.com Mark Cuban Isn't Convinced TrumpRx Is Going To 'Change The Game' But He's Giving Them 'Credit For Trying' Billionaire entrepreneur Mark Cuban offered rare praise for the Trump administration's push to lower prescription drug costs, calling its TrumpRx initiative "a good start," while still acknowledging…- benzinga.com GoodRx Launches $16/Month Subscription For Hair Loss Treatment With Virtual Care And Home Delivery The all-in-one solution includes a virtual consultation, clinically proven prescription medication, and discreet home delivery, starting as low as $16/monthGoodRx (NASDAQ:GDRX), the leading platform…